Hims & Hers Health, Inc.

Case Overview
41 Days Left to Seek Lead Plaintiff
Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 08/25/2025 |
Status: | Status: Investigating |
Company Name: | Company Name: Hims & Hers Health, Inc. |
Court: | Court: Northern District of California |
Case Number: | Case Number: 3:25cv05315 |
Class Period: | Class Period: 04/29/2025 - 06/23/2025 |
Ticker: | Ticker: HIMS |
Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Northern District of California on behalf of those who acquired Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”) (NYSE: HIMS) securities during the period of April 29, 2025 through June 23, 2025, inclusive (“the Class Period”). Investors have until August 25, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
On April 29, 2025, Hims & Hers and Novo Nordisk announced a “long-term collaboration” under which Hims & Hers would sell Novo Nordisk’s popular weight loss drug Wegovy. On June 23, 2025, Novo Nordisk announced that it was terminating the partnership, accusing Hims & Hers of engaging in “deceptive marketing” and the illegal “selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.” On this news, the price of Hims & Hers shares declined $22.25 per share, or approximately 34%, from $64.22 per share on June 20, 2025 to $41.97 per share on June 23, 2025.
The lawsuit alleges that Hims & Hers failed to disclose to investors that: (1) the Company was engaged in the deceptive promotion and sale of illegitimate, knockoff versions of Wegovy that endangered patients; and (2) as a result, there was a substantial risk that the Company’s collaboration with Novo Nordisk would be terminated.
On April 29, 2025, Hims & Hers and Novo Nordisk announced a “long-term collaboration” under which Hims & Hers would sell Novo Nordisk’s popular weight loss drug Wegovy. On June 23, 2025, Novo Nordisk announced that it was terminating the partnership, accusing Hims & Hers of engaging in “deceptive marketing” and the illegal “selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.” On this news, the price of Hims & Hers shares declined $22.25 per share, or approximately 34%, from $64.22 per share on June 20, 2025 to $41.97 per share on June 23, 2025.
The lawsuit alleges that Hims & Hers failed to disclose to investors that: (1) the Company was engaged in the deceptive promotion and sale of illegitimate, knockoff versions of Wegovy that endangered patients; and (2) as a result, there was a substantial risk that the Company’s collaboration with Novo Nordisk would be terminated.